icon-folder.gif   Conference Reports for NATAP  
 
  IDWeek
October 3 -7, 2018
San Francisco, CA
Back grey_arrow_rt.gif
 
 
 
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment-naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load, CD4+ Count, and WHO Clinical Staging
 
 
  Reported by Jules Levin
IDWeek 2018, October 3-7, 2018, San Francisco
 
Christoph D. Spinner,1 Bruce Rashbaum,2,* Cheryl McDonald,3 Cristina Mussini,4 Donghan Luo,5 John Jezorwski,6 Kimberley Brown,5 Eric Y. Wong7
1Technische Universitat Munchen, Munich, Germany; 2Capital Medical Associates, Washington, DC, USA; 3Tarrant County Infectious Disease Associates, Fort Worth, TX, USA; 4University of Modena and Reggio Emilia, Modena, Italy; 5Janssen Research & Development, LLC, Titusville, NJ, USA;
6Janssen Research & Development, LLC, Pennington, NJ, USA; 7Janssen Scientific Affairs, LLC, Titusville, NJ, USA

1003181

1003182

1003183

1003184

1003185

1003186

1003187

1003188

1003189